Research

HS research update (2026-09-01): What’s new on PubMed?

A patient-friendly overview of new PubMed publications on hidradenitis suppurativa (acne inversa) — with sources, clear limitations, and no medical advice.

Published

Last updated

Written by Dr. rer. nat. Dennis Alexander Kwiatkowski

Publication overview

This update includes 28 PubMed publications with abstracts from the monitoring window 2026-08-18 to 2026-09-01. The most common themes are biologicsBiologic: A class of medications derived from living cells that target specific components of the inflammatory process. For Acne Inversa, biologics such as adalimumab and secukinumab are used when other treatments are insufficient., pain, quality of life, comorbiditiesComorbidity: An additional condition existing alongside the primary disease. Acne Inversa is frequently associated with comorbidities including metabolic syndrome, inflammatory bowel disease, spondyloarthritis, and depression., wound care.

  • Compared with the previous update: not automatically assessed.
  • No guideline/NEJM/Lancet-style high-impact matches with abstracts in this window.
  • This is a research overview, not a guideline update or medical recommendation.

Top highlights

The most useful signal this round is not a single treatment instruction. It is what researchers are looking at more closely: wound healing after procedures, possible new anti-inflammatory approaches, care quality, and comorbidities.

  • IL-17 treatment and side-effect management: This paper focuses on mucocutaneous candidiasis during bimekizumabBimekizumab: A monoclonal antibody blocking both IL-17A and IL-17F. Approved by the FDA on 20 November 2024 as the first IL-17A and IL-17F inhibitor for adults with moderate-to-severe HS; approved by the EMA in April 2024. Brand name: Bimzelx®. therapy for HS. The new angle is practical: how prevention and early management of a known IL-17-pathway adverse event might affect tolerability and treatment persistence. (PMID 42663860)
  • Surgical Management of Hidradenitis Suppurativa: Postoperative Outcomes Following Complete Regional Excision With Secondary Intent Healing Versus Suture-Closure Techniques.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodulesNodule: A firm, palpable lump deep in tissue. Nodules can be painful and may progress to abscesses. They are among the typical early signs of Acne Inversa., abscessesAbscess: An inflamed cavity or swelling containing pus or fluid. In hidradenitis suppurativa, abscesses can form as part of the inflammatory disease process and do not automatically mean that a bacterial infection is present. Secondary bacterial infection can occur and may require separate medical assessment. In Acne Inversa, abscesses occur mainly in the armpits, groin, and other skin folds., and subcutaneous tunnelsSinus Tract: A tunnel-like channel under the skin that forms between abscesses or nodules. Sinus tracts indicate more advanced disease and can chronically drain fluid. They are associated with Hurley Stages II and III.. HS often leads to intractable draining wounds and scarring. What makes it notable here is that it approaches HS through wound care, pain, surgery. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42642907)
  • SecukinumabSecukinumab: A biologic drug that inhibits the inflammatory messenger interleukin-17A (IL-17A). Secukinumab was approved as the second biologic for treating Acne Inversa and is available under the brand name Cosentyx®. in moderate to severe hidradenitis suppurativa: effectiveness and safety in real-world clinical practice.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic skin disease in which interleukin17 (IL-17) plays a significant role. Secukinumab, a monoclonal antibody that selectively blocks the action of IL-17A, is one of the approved… What makes it notable here is that it approaches HS through quality of life, pain, biologics. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42641491)
  • Factors influencing quality of life in hidradenitis suppurativa: Data from 1188 patients.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that severely impacts patients’ quality of life (QoL). Instruments commonly used to evaluate QoL in people with dermatological conditions, such as t… What makes it notable here is that it approaches HS through quality of life, comorbidities, pain. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42627116)
  • Quality of Life in Patients with Hidradenitis Suppurativa: A Scoping Review.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Background/Objectives: Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease associated with a significant impairment in patients’ quality of life (QoL). However, evidence on QoL assessment in HS remain… What makes it notable here is that it approaches HS through quality of life, pain. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42646550)

The featured paper is Quality of Life in Patients with Hidradenitis Suppurativa: A Scoping Review. in Nursing reports (Pavia, Italy) (PMID 42646550). The abstract mainly says this: Background/Objectives: Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease associated with a significant impairment in patients’ quality of life (QoL). However, evidence on QoL assessment in HS remain…

Why it stands out: it connects to the priority themes quality of life, pain and shows what HS researchers are trying to clarify right now. For readers, it matters because it gives one concrete example of how the field is framing a practical question or possible mechanism. The main limitation is that From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full.

What this may mean for patients (carefully, no advice)

If you live with HS, research updates can help you make sense of what’s being studied — for example which outcomes (pain, quality of life) researchers measure, or which comorbidities are increasingly part of the conversation.

But even when a study sounds promising, it usually does not tell you what is right for you personally. Consider using new findings as questions for your next appointment (e.g., “What are realistic goals for me?” or “Which related conditions should we keep an eye on?”), not as instructions.

What we don’t know / limitations

  • This update includes only PubMed items with an abstract (without an abstract, safe summarization is limited).
  • Studies vary widely (design, populations, outcome measures).
  • This update provides no treatment advice and cannot assess individual risk.

Important: decisions belong in clinician conversations

This article is an editorial overview and is not medically reviewed. If something here worries or interests you, use it as a conversation starter for your next appointment. Decisions should always be made with qualified healthcare professionals.

FAQ

Why are there only a few new publications here?

This format is deliberately strict: it includes only new PubMed items from the monitoring window that have an abstract and were not already covered in earlier posts.

Does a new paper mean my treatment should change?

No. A single publication can be useful to know about, but it is usually not enough to guide decisions for one specific person.

Why emphasize limitations so much?

Because abstracts show only part of the picture. Study design, patient population, endpoints, and follow-up all matter before results can be interpreted responsibly.

Sources & original papers

Each point below maps to an original source (PubMed link, plus DOI/PMCID when available).

Terms explained in this article

Quick definitions of the key medical terms. Select any term for its full glossary entry.

Biologic
A class of medications derived from living cells that target specific components of the inflammatory process. For Acne Inversa, biologics such as adalimumab and secukinumab are used when other treatments are insufficient.
Comorbidity
An additional condition existing alongside the primary disease. Acne Inversa is frequently associated with comorbidities including metabolic syndrome, inflammatory bowel disease, spondyloarthritis, and depression.
Bimekizumab
A monoclonal antibody blocking both IL-17A and IL-17F. Approved by the FDA on 20 November 2024 as the first IL-17A and IL-17F inhibitor for adults with moderate-to-severe HS; approved by the EMA in April 2024. Brand name: Bimzelx®.
Nodule
A firm, palpable lump deep in tissue. Nodules can be painful and may progress to abscesses. They are among the typical early signs of Acne Inversa.
Abscess
An inflamed cavity or swelling containing pus or fluid. In hidradenitis suppurativa, abscesses can form as part of the inflammatory disease process and do not automatically mean that a bacterial infection is present. Secondary bacterial infection can occur and may require separate medical assessment. In Acne Inversa, abscesses occur mainly in the armpits, groin, and other skin folds.
Sinus Tract
A tunnel-like channel under the skin that forms between abscesses or nodules. Sinus tracts indicate more advanced disease and can chronically drain fluid. They are associated with Hurley Stages II and III.
Secukinumab
A biologic drug that inhibits the inflammatory messenger interleukin-17A (IL-17A). Secukinumab was approved as the second biologic for treating Acne Inversa and is available under the brand name Cosentyx®.

References

  1. Part II. Measuring skin pain in humans: Quantitative, psychophysical, and patient-reported tools for dermatology. The Journal of investigative dermatology, 2027 — PMID 42615959 · DOI 10.1016/j.jid.2026.02.028
  2. Predictors of adalimumab durability in hidradenitis suppurativa: a multicenter cohort study. The Journal of dermatological treatment, 2026 — PMID 42619449 · DOI 10.1080/09546634.2026.2719076
  3. Role of Ultrasonography in the Diagnosis and Treatment of Hidradenitis Suppurativa: A Narrative Review. Indian dermatology online journal, 2026 — PMID 42671431 · DOI 10.4103/idoj.idoj_716_25
  4. Post-Transcriptional Regulators of Inflammation: The Role of microRNAs in Acne Inversa Pathogenesis. Journal of biochemical and molecular toxicology, 2026 — PMID 42670831 · DOI 10.1002/jbt.71072
  5. Neuropathic Pain Management Using Novel Biologics in Moderate-to-Severe Hidradenitis Suppurativa. Current pain and headache reports, 2026 — PMID 42671722 · DOI 10.1007/s11916-026-01551-y
  6. Dissecting Cellulitis and Hidradenitis Suppurativa: Two Diseases or One Follicular-Occlusion Spectrum? International journal of dermatology, 2026 — PMID 42667534 · DOI 10.1111/ijd.70661
  7. Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS). Dermatology and therapy, 2026 — PMID 42663860 · DOI 10.1007/s13555-026-01891-y
  8. Association of dietary sodium intake with IL-17-mediated diseases in the UK Biobank. Clinical nutrition ESPEN, 2026 — PMID 42660497 · DOI 10.1016/j.clnesp.2026.105065
  9. Surgical Management of Hidradenitis Suppurativa: Postoperative Outcomes Following Complete Regional Excision With Secondary Intent Healing Versus Suture-Closure Techniques. International journal of dermatology, 2026 — PMID 42642907 · DOI 10.1111/ijd.70645
  10. Secukinumab in moderate to severe hidradenitis suppurativa: effectiveness and safety in real-world clinical practice. Medicina clinica, 2026 — PMID 42641491 · DOI 10.1016/j.medcli.2026.107562
  11. Dietary patterns in western patients with hidradenitis suppurativa: a cross-sectional study using the rapid prime diet quality screener. Scientific reports, 2026 — PMID 42634079 · DOI 10.1038/s41598-026-53399-2 · PMCID PMC13500541
  12. Evaluation of the Nrf2-Keap1 and Sestrin-2 Pathways in the Serum of Patients with Hidradenitis Suppurativa. Medicina (Kaunas, Lithuania), 2026 — PMID 42654508 · DOI 10.3390/medicina62081611 · PMCID PMC13515055
  13. Factors influencing quality of life in hidradenitis suppurativa: Data from 1188 patients. Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42627116 · DOI 10.1111/jdv.70663
  14. Distinct spondyloarthritis phenotypes and disease burden in patients with concomitant hidradenitis suppurativa. Seminars in arthritis and rheumatism, 2026 — PMID 42664532 · DOI 10.1016/j.semarthrit.2026.153062
  15. Quality of Life in Patients with Hidradenitis Suppurativa: A Scoping Review. Nursing reports (Pavia, Italy), 2026 — PMID 42646550 · DOI 10.3390/nursrep16080289 · PMCID PMC13516480
  16. Disseminated herpes zoster with pulmonary lesions mimicking miliary tuberculosis in an HIV-infected patient previously treated with adalimumab: A case report. IDCases, 2026 — PMID 42666869 · DOI 10.1016/j.idcr.2026.e02732 · PMCID PMC13524448
  17. Clascoterone in the Treatment of Acne Vulgaris: A Narrative Review. Pharmaceuticals (Basel, Switzerland), 2026 — PMID 42653799 · DOI 10.3390/ph19081304 · PMCID PMC13516472
  18. Serum Asprosin Levels in Patients with Hidradenitis Suppurativa: A Case-Control Study. Diagnostics (Basel, Switzerland), 2026 — PMID 42651022 · DOI 10.3390/diagnostics16162621 · PMCID PMC13512244
  19. Corrigendum: Assessment of Altmetrics and PlumX Metrics Scoring as Mechanisms to Evaluate the Top 100 Trending Hidradenitis Suppurativa Articles on Social Media: Cross-Sectional Study. JMIR dermatology, 2026 — PMID 42612212 · DOI 10.2196/106381
  20. European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment. Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42610770 · DOI 10.1111/jdv.70638
  21. Type 17 T-cell subset divergence in hidradenitis suppurativa versus psoriasis: a comparative single-cell transcriptomic analysis. Frontiers in immunology, 2026 — PMID 42666328 · DOI 10.3389/fimmu.2026.1835460 · PMCID PMC13522199
  22. Intrinsic Dysregulation and Environmental Modifiers in Hidradenitis Suppurativa: Toward an Integrated Pathophysiologic Model. Journal of clinical medicine, 2026 — PMID 42652658 · DOI 10.3390/jcm15166256 · PMCID PMC13513508
  23. Epithelial skin cancer before, during, and after the COVID-19 pandemic. Frontiers in medicine, 2026 — PMID 42620664 · DOI 10.3389/fmed.2026.1833019 · PMCID PMC13485737
  24. Exploring the Social, Emotional, and Physical Consequences of Hidradenitis Suppurativa in Pediatric Patients: A Scoping Review. Pediatric reports, 2026 — PMID 42646648 · DOI 10.3390/pediatric18040103 · PMCID PMC13516647
  25. Peripheral Ulcerative Keratitis Secondary to Hidradenitis Suppurativa: A Case Report. Nigerian journal of clinical practice, 2026 — PMID 42671451 · DOI 10.4103/njcp.njcp_792_25
  26. Hidradenitis Suppurativa on TikTok: Representation, Treatment Messaging, and Psychosocial Themes. Cureus, 2026 — PMID 42669015 · DOI 10.7759/cureus.113677 · PMCID PMC13525858
  27. Patient-Level Risk Characterization of Drug-Associated Hidradenitis Suppurativa Using Machine Learning. medRxiv : the preprint server for health sciences, 2026 — PMID 42619801 · DOI 10.64898/2026.05.04.26352179 · PMCID PMC13484310
  28. Diffuse large B-cell lymphoma of the axilla clinically mimicking hidradenitis suppurativa. Wounds : a compendium of clinical research and practice, 2026 — PMID 42640995 · DOI 10.25270/wnds/25102